Acute Myeloid Leukemia (AML)

Katherine Tarlock, M.D., is a board certified physician at Seattle Children’s Hospital and a UW assistant professor of pediatrics. Dr. Tarlock believes the privilege of caring for patients and families during challenging medical diagnoses is what drew her to this field and continues to be the best part of her job. She is dedicated to advancing our understanding of leukemia and being able to offer every child and family the best care. Dr. Tarlock earned her M.D. at Chicago Medical School. She is board certified in both Pediatrics and Pediatric Hematology/Oncology.

Dr. Shaffer is a board certified hematologist specializing in bone marrow transplantation for leukemia, myelodysplastic syndromes, lymphoma, and other bone marrow disorders. He works in a collaborative fashion with other members of our team to provide comprehensive cancer care at Memorial Sloan Kettering Cancer Center. His research focuses on the role of Natural Killer (NK) cells in outcomes after transplantation. NK cells are white blood cells that have anti-tumor and anti-infection properties. His goal is to improve the transplantation process for patients via understanding and optimizing NK

Dr. Hasserjian's clinical work and research focus on myeloid neoplasia. He has served on the Executive Committee of the Society for Hematopathology and on the Education Committee of the United States and Canadian Academy of Pathology. Dr. Hasserjian is a member of the Pathology Advisory Committee for the World Health Organization Classification of Myeloid Neoplasms. Dr. Hasserjian is a dedicated medical educator, and director of the Hematopathology Fellowship at Massachusetts General Hospital.

Dr. Niyongere joined the School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center as an Assistant Professor in 2018. Her clinical focus is in acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms and bone marrow failure syndromes. Dr. Niyongere’s primary research interests are in finding new therapeutic targets by understanding oncogenic signaling pathways involved in AML and MDS as well as studying the role of the tumor microenvironment in the development of chemoresistance in leukemia. Dr. Niyongere also serves as an attending physician on the